| Dataset | DGIdb Drug Targets 2026 |
| Category | physical interactions |
| Type | drug |
| Description | A C-glycosyl compound consisting of a beta-glucosyl residue having a (4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl group at the anomeric centre. A sodium-glucose co-transporter 2 inhibitor used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. (Chemical Entities of Biological Interest Ontology, CHEBI_82720) |
| External Link | https://dgidb.org/results?searchType=drug&searchTerms=EMPAGLIFLOZIN |
| Similar Terms | |
| Downloads & Tools |
5 interacting proteins for the EMPAGLIFLOZIN drug from theDGIdb Drug Targets 2026 dataset.
| Symbol | Name | Standardized Value |
|---|---|---|
| ATP2A2 | ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 | 3.5288 |
| SLC5A2 | solute carrier family 5 (sodium/glucose cotransporter), member 2 | 1.3233 |
| SLC5A4 | solute carrier family 5 (glucose activated ion channel), member 4 | 0.8822 |
| SLC5A1 | solute carrier family 5 (sodium/glucose cotransporter), member 1 | 0.622729 |
| BDNF | brain-derived neurotrophic factor | 0.199743 |